Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Disease × Gemcitabine × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 87 Neoplasms 26 Carcinoma, Non-Small-Cell Lung 25 Neoplasm Metastasis 20 Urinary Bladder Neoplasms 15 Colorectal Neoplasms 13 Sarcoma 12 Lymphoma, Large B-Cell, Diffuse 11 Lung Neoplasms 11 Breast Neoplasms 11 Biliary Tract Neoplasms 11 Ovarian Neoplasms 9 Lymphoma 9 Recurrence 7 Hodgkin Disease 7 Cholangiocarcinoma 7 Carcinoma, Transitional Cell 7 Non-Muscle Invasive Bladder Neoplasms 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Follicular 6 Adenocarcinoma 6 Small Cell Lung Carcinoma 5 Gastrointestinal Neoplasms 5 Triple Negative Breast Neoplasms 4 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Advanced Solid Tumor 4 Urethral Neoplasms 3 Rectal Neoplasms 3 Prostatic Neoplasms 3

Interventions

carfilzomib 2 Dexamethasone 2 Cyclophosphamide 2 tivozanib 1 tislelizumab 1 pembrolizumab 1 neratinib 1 Nivolumab 1 Interleukin-15 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Cisplatin 1 Capecitabine 1 Calcium Dobesilate 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01730222 2017-09-01

PACT-19

IRCCS San Raffaele

Phase 1/2 Completed

Gastrointestinal

Disease, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡